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Abstract 
 Gonadotropin-releasing hormone (GnRH) receptors are overexpressed on many cancer 
cells but not on primary cell lines. This study was designed to investigate the targeting ability 
and uptake of dendritic lipidated [Gln
1
]-GnRH peptide analogues on receptor-positive 
prostate cancer PC-3 cells relative to receptor-negative ovarian carcinoma SKOV-3 cells for 
potential application in drug delivery. Direct antiproliferative effect of these was investigated 
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on three GnRH-receptor positive cancer cells, PC-3, LNCaP and DU145. A significant dose 
dependent growth inhibitory effect was produced in DU145 cells by 5 dendrimers giving an 
IC50 value of 22-35 µM. All compounds were non-toxic to the normal peripheral blood 
mononuclear cells.  
 
Keywords 
Gonadotropin-releasing hormone 
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Prostate cancer 
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Background 
 Gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone releasing 
hormone, is a decapeptide (p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly) produced in the 
hypothalamus. This peptide regulates the pituitary-gonadal axis, thus the reproductive 
system.[1-3] GnRH receptors are characteristically overexpressed in many tumours, such as 
breast, ovarian, pancreatic, and prostate.[1, 3-7] By contrast, the expression of GnRH 
receptors is not detectable in normal tissue.[1, 3-7] The elevated expression of GnRH 
receptors on tumour cells makes it possible to specifically target and deliver cytotoxic agents 
to these cells.[1, 2, 4, 8] 
 
 Prostate cancer is the most prevalent form of cancer in men and the second leading cause 
of death (in men) in Western countries.[5, 9]
 
First line therapies for managing prostate cancer 
are localised treatments such as radiotherapy and/or prostatectomy followed by second-line 
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hormone-based therapies including GnRH agonists and antagonists.[1, 2, 5, 10] Recent 
studies have taken advantage of this differential receptor expression and used a modified 
GnRH peptide as a targeting moiety to enhance the relative uptake by cancer cells and 
decrease the relative availability to normal cells.[1, 2, 4, 8, 11] Targeting anticancer drugs to 
tumours may assist in improving the drugs specificity, reducing toxicity to normal cells, and 
reducing the possibility of multidrug resistance.[3-5] 
 
 GnRH analogues are recognised by a broad variety of GnRH-receptor positive, but not 
receptor negative, cells.[4, 6, 12] Using small peptides instead of conventional protein 
macromolecules has many advantages including ease of preparation, lower antigenicity, and 
increased stability.  GnRH analogue-modified carriers have been used for selective delivery 
of diagnostic and therapeutic agents to cancer cells that overexpress the GnRH receptor.[4, 
13] This ligand-targeted delivery results in increased internalisation and more effective 
delivery of anticancer drugs, thus overcoming the problem of multidrug resistance and toxic 
effects of cytotoxic drugs on normal cells.[8, 13] Extension of the GnRH C- and N-terminals 
by addition of lipids improves the half-life of the peptide when used in oral drug delivery 
applications.[14]  
 
 Natural lipidation of proteins causes a change in hydrophobicity and conformation, which 
promotes localisation to specific subcellular compartments.[15] In this study, lipids were 
included in the constructs to aid peptide self-assembly and to increase drug targeting 
potential.[13, 16, 17] It is known that hydrophobic modifications such as the posttranslational 
lipidation of proteins can result in higher membrane binding affinity, thereby affecting 
protein localisation and functioning.  
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 Single lipid modification of the proteins typically allowed limited membrane affinity 
resulting in rapid dissociation from the membrane.[15, 18, 19] A number of thermodynamic 
studies have investigated the membrane binding properties of small lipidated peptides and 
proteins. A single unbranched lipid modification was insufficient to anchor a lipidated protein 
into the membrane but a second or third lipid modification provided sufficient binding energy 
for permanent membrane association. This lipid binding was counteracted by the polar nature 
of the peptide backbone and presence of charged amino acid side chains which prevented full 
membrane insertion.[15, 18, 19]  
 
 In the present study, lipids were assembled on a poly-lysine core which was included to 
enhance self-assembly properties. The peptide analogue [Gln
1
]-GnRH (GnRH-1) was 
included as a targeting agent (Figure 1).  
 
 To investigate whether lipidated GnRH-1 analogues could be specifically targeted in vitro 
towards GnRH-receptor positive cells, their uptake into PC-3 prostate cancer cells was 
compared to that of GnRH-receptor negative SKOV-3 ovarian cancer cells. Furthermore, the 
direct effect of these GnRH-1 analogues was examined in vitro on the proliferation of three 
classic GnRH-receptor positive tumour cell lines; PC-3, LNCaP, DU145, and normal 
peripheral blood mononuclear cells (PBMCs) isolated from whole blood.  
 
Methods 
General  
Dimethylformamide (DMF), trifluoroacetic acid (TFA), and piperidine of peptide 
synthesis grade were purchased from Merck Biosciences (Kilsyth, VIC, Australia). 5(6)-
carboxyfluorescein (5-FAM) was purchased from Sigma Aldrich (St Louis, MO, USA). 
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HPLC-grade acetonitrile (MeCN) was purchased from RCI Labscan Ltd. (Bangkok, 
Thailand). Fmoc-protected amino acids and Rink amide MBHA resin (100–200 mesh, 0.4–
0.8 mmol/g loading) were obtained from Novabiochem (Melbourne, VIC, Australia) or 
Mimotopes (Clayton, VIC, Australia). Preparative HPLC was carried out on a Shimadzu 
system equipped with a CBM-20A controller, LC-20AT pump, SIL-10A autosampler, SPD-
20A UV/Vis detector set to a wavelength of 230 nm and a FRC-10A fraction collector. The 
analytical HPLC was a Shimadzu instrument with an L -20AB pump, a SIL-20AHT 
autosampler and an SPD-M10A detector set to a wavelength of 214 nm. Electrospray 
ionisation mass spectrometry (ESI-MS) was performed on a PE Sciex API3000 triple 
quadrupole mass spectrometer, operating with a constant flow of a 1:1 mixture of solvent A 
(0.1% formic acid in water) and B (0.1% formic acid in MeCN/water 9:1) at a rate of 0.05 
ml/min. A Zetasizer Nano ZP instrument (Malvern Instruments, UK) with DTS software was 
used for particle size measurements. Sizes were analysed using a non-invasive backscatter 
system. Measurements were taken at 25 °C with scattering angle of 173° using disposable 
cuvettes. PC-3, a human prostate cancer cell line and SKOV-3, a human ovarian cancer cell 
line, were obtained from American Type Culture Collection (Manassas, VA, USA). The 
LNCaP and DU145 human cell lines were kindly provided by Prof. Judith Clements at 
Translational Research Institute, Queensland University of Technology. Dulbecco’s Modified 
Eagle’s Medium (DMEM), penicillin/streptomycin, TrypLE Express, fetal bovine serum 
(FBS), and Alexa Fluor 647 were obtained from Life Technologies Australia (Mulgrave, 
VIC, Australia). Vectorshield® mounting medium with DAPI was from Vector Laboratories, 
Inc., (Burlingame, CA, USA). Flow cytometry was performed on a FACSCantoTM flow 
cytometer (BD Biosciences, North Ryde, NSW, Australia).  
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Peptide synthesis 
Manual Solid-phase peptide synthesis 
Peptides were assembled step-wise on Rink amide MBHA resin (0.2 mmol scale) 
using the in situ neutralisation protocol for Fmoc solid phase peptide synthesis (SPPS).[20] 
N-Fmoc-protected amino acids (4.2 eq.) were activated with HATU (4 eq.) and DIPEA (5 
eq.) and coupled twice for a minimum of 45 min. The following side chain protecting groups 
were used: Lys(Fmoc), Arg(Pbf), Tyr(tBu), Ser(tBu), Trp(Boc), His(Trt) and Gln(tBu). The 
Fmoc protecting group was removed by treatment with 20% piperidine in DMF for 5 min and 
15 min, respectively. 2-(4, 4-Dimethyl-2, 6-Dioxocyclohex-1-ylidene) lipoamino acid [C12-
LAA] was synthesised according to a previously published procedure [21] and N-protected 
with 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl (Dde) [22] which was removed by 
treatment with 2% hydrazine hydrate in DMF (2 × 1.5 h). 5-FAM (2.5 eq.) was coupled to the 
resin using HOBT (2.5 eq.) and DIC (2.5 eq.) in DMF (2 x 1 h) in the dark. Additional ester-
bound 5-FAM was removed by treating the resin with 20% piperidine (6 x 5 min, 6 x 15 
min). Once the peptide sequence was complete, the resin was washed with DMF, MeOH and 
DCM, and dried under vacuum overnight. The peptide was cleaved by stirring the resin in a 
mixture of TFA, water and triisopropyl silane (9.5:2.5:2.5) for 3 h. Addition of cold diethyl 
ether precipitated the peptide, the solvent was discarded, and the peptide dissolved in a 
mixture of MeCN and water (1:1) containing 0.1% TFA then lyophilised. 
 
Purification and Characterisation 
Crude peptides 5 and 6 were purified by preparative RP-HPLC using a Vydac C18 
column (22 mm × 250 mm) with a gradient of 100% A (water, 0.1% TFA) to 100% B (90% 
MeCN in water, 0.1% TFA) over 60 min at a flow rate of 20 ml/min. Crude GnRH-1. 
Analogues (1-4, s1-s4) were purified by preparative RP-HPLC using a Vydac C4 column (22 
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mm × 250 mm) with a gradient of 100% A to 100% B over 60 min at a flow rate of 20 
ml/min. The collected fractions from 5 and 6 were analysed by analytical HPLC using a 
Vydac C18 (4.6 mm × 250 mm, 5 µm) and a Vydac C8 column (4.6 mm × 250 mm, 5 µm) 
with a gradient of 100% A to 100% B over 30 min at a flow rate of 1 ml/min. The fractions 
from 1-4, s1-s4 were analysed by analytical HPLC using a Vydac C4 column (4.6 mm × 250 
mm, 5 µm) with the same gradient and solvent as listed for analogues 5 and 6. Fractions that 
contained pure peptide were combined and lyophilised. Yields and characterisation by HPLC 
and ESI-MS is shown in Table 1. 
 
Particle Size and Zeta Potential Measurement 
Lyophilised peptides were dispersed by vortexing in deionised water at a 
concentration of 1 mg/ml and leaving for 60 min prior to analysis. Measurements were 
performed in triplicate.  
 
Tissue Culture 
All cells were maintained in T-75 flasks at 37 °C in a humidified atmosphere of 5% 
CO2 and 95% air. PC-3 and SKOV-3 were cultured in DMEM, LNCaP and DU145 in RPMI-
1640 that was supplemented with 10% FBS, penicillin/streptomycin and 1% non-essential 
amino acids. 
 
Uptake by Flow Cytometry  
SKOV-3 and PC-3 cells were seeded into 24-well plastic plates at a density of 1.0 x 
10
5
 cells per well and allowed to adhere overnight. Culture medium was removed and 
replaced with fresh DMEM that contained fluorescently-labelled GnRH-1 peptides at 10 µM 
and the cells were incubated for a further 4 h at 37 °C. Cells were washed with 1 ml PBS (3x) 
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and trypsinised using TrypLE Express (0.1 ml) for 5 min at 37 °C before being resuspended 
in 0.6 ml PBS and placed into tubes for flow cytometry. To detect the intracellular 
concentration of peptide, cells were treated with trypan blue (TB, 0.4%) 30 seconds prior to 
flow analysis to quench the surface-bound fluorescence.[23] Cells grown in the absence of 
GnRH-1 analogues were used as controls.  
 
Fluorescence Microscopy  
Cells were seeded and treated as per flow cytometry experiments. After 4 h incubation 
with the labelled peptide, cells were washed with 1 ml PBS (3x), treated with TB (0.4%) to 
quench surface bound peptide, and washed with 1 ml PBS. Cells were visualised using an 
Olympus IX51 inverted fluorescence microscope. 
 
Triptorelin Competition Assay  
SKOV-3 and PC-3 cells were seeded on coverslips in 12-well plastic plates at a 
density of 1.0 x 10
5
 cells per well and allowed to adhere overnight. Medium was removed 
and replaced with 0.5 ml fresh DMEM that contained triptorelin at a concentration of 100 µM 
and incubated at 37 °C for 30 min. Cells were then incubated in DMEM that contained 
Compound 4 (1 µM and 10 µM) at 37 °C for an additional 4 h. Cells were washed with 1 ml 
PBS (3x) and fixed with 4% formaldehyde in cytoskeletal buffer [24] at RT for 30 min. The 
cells were washed with 1 ml PBS (3x). For F-actin staining, cells were incubated with Alexa 
Fluor 647 for 45 min at RT and mounted using Vectorshield mounting medium with DAPI. 
Slides were visualised using an Olympus BX61 confocal microscope. 
 
Calculations 
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Binding index was calculated as a ratio of geometric mean fluorescence of PC-3 and 
SKOV-3 cells (fluorescence relative to negative control) in order to normalise fluorescence in 
both cell lines. Data are presented as mean ± SD. Differences between groups was 
determined using two-way analysis of variance (ANOVA) followed by the Tukey post hoc 
test and were considered statistically significant if P value was <0.05.  
Isolation of peripheral blood mononuclear cells (PBMCs) 
Assay was performed with the approval from the University of Queensland Ethics 
Committee (Ethical Approval Number: 2009000661). A blood sample (4 mL) was collected 
from a healthy adult volunteer and diluted with the same volume of RPMI. Diluted blood was 
overlayed with 4 mL Ficoll and centrifuged at 400 g for 30 min. The white cell interface 
including mononuclear cells was removed and washed with RPMI 1640 (3x). Cells were 
resuspended in 10% FBS:RPMI and seeded at 1x10
6 
cells/mL in a 96-well flat bottom plate 
(TPP), activated by adding 10 µg/mL of phytohemagglutinin and incubated at 37 °C in a 5% 
CO2 atmosphere. After 1 h incubation, GnRH-1 compounds were added at 10 µL/well in 10% 
DMSO:PBS at 25 and 50 µM. MTT assay was performed after 48 h incubation with the same 
method as described in cell the growth assay. 
In vitro cell growth assay 
Cell proliferation was evaluated by MTT assay as published previously.[25]
 
Briefly 
cells were seeded at 2.0 x 10
4
 cells/well and allowed to attach for 1 h. GnRH-1 compounds 
were added at different concentrations (25 and 50 µM for PC-3, LNCaP and 10, 50, 100 and 
200 µM for DU145 cells). After 48 h incubation, 10 µL MTT (5 mg/mL) was added to each 
well. Plates were incubated for a further 4 h. Formazan crystals were dissolved using 100 µL 
acidified isopropanol (0.1 N HCl). A Spectramax 250 microplate reader was used to measure 
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the absorbance of each well at 570 nm. The percentage of cell viability for each compound 
was calculated by comparing absorbance with PBS negative control. SDS was used as a 
positive control. 
 
Results  
Peptide Synthesis and Characterisation 
The amino acid sequences of the GnRH-1 derivatives and triptorelin ([w
6
]-GnRH, a 
clinically available superagonist) are shown in Figure 1 and Table 1, respectively. Pure 
lipidic peptides were readily synthesised using step-wise Fmoc SPPS (see Supplementary 
Information for a detailed synthetic scheme). The lipidic moiety consisting of two synthetic 
lipoamino acids was synthesised as a diastereomeric mixture at the C- or N-terminus of the 
constructs (Figure 1). A fluorescent tag (5-FAM, Figure 1) was coupled to the N-terminus of 
the GnRH-1 analogues using HOBT and DIC. This step was performed in the dark to limit 
photo-bleaching. Removal of additional fluorophore esters was achieved by subsequent 
treatment of the resin with piperidine or until no further colour was observed when washed. 
This diastereomeric mixture resulted in broad or twin peaks in HPLC for each lipidated 
peptide analogue with a single peak observed for non-lipidated peptides (see Supplementary 
information). Following TFA cleavage, all crude compounds were purified by PR-HPLC 
using C18 or C4 column to >98% purity. The lyophilised peptides were obtained in 22-63% 
yields, characterised by ESI-MS and their purity confirmed by analytical HPLC (Table 1). 
Incorporation of the lipids results in a diastereomeric mixture that was not separated prior to 
in vitro analysis. Peptide dendrimers were assessed for their relative nanoparticular size in 
water to identify any significant changes between the N- and C-terminal lipidated constructs. 
In this study all peptides were greater than 100 nm in diameter (Table 2). 
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In Vitro Evaluation 
Cell Uptake study  
In vitro GnRH receptor-mediated uptake and internalisation of the GnRH-1 analogues 
was evaluated using GnRH-receptor over expressing PC-3 cells and low expressing SKOV-3 
cells by flow cytometry and microscopy. TB was used as an extracellular quencher to 
distinguish between cell-associated fluorescence and fluorescence due to internalisation of 
peptide analogues. Optimisation of TB quenching (data not shown) was performed and found 
that addition of 0.4% TB 30 seconds before flow analysis gave higher quenching than 
addition of TB prior to the cell trypsination step.  
 
 Peptide concentration and incubation times were optimised in preliminary studies (data 
not shown).  
 
Cellular internalisation of GnRH-1 analogues to PC-3 cells relative to SKOV-3 cells 
exhibited no significant difference for all compounds except analogues 1, 4 and 6 (Figure 2). 
Analogues s1-s4, containing the scrambled GnRH-1 peptide, was used as controls to show 
non-specific binding towards each cell line. Here, no significant difference in internalisation 
by PC-3 cells was observed between analogues 2 and 3 when compared to the scrambled 
analogues, s2 and s3. However, significant internalisation was observed between 1 and s1, 
and 4 and s4 (Figure 2). Interestingly, analogues 4 and 6 showed the highest binding to PC-3 
cells (Figure 2 and 3). Both contained the bi-GnRH-1 peptide with 4 containing an N-
terminal lipid (Figure 1).  
 
Examination of cellular uptake using fluorescence microscopy indicated that 
internalisation had occurred with GnRH-1 analogues in PC-3 but not in SKOV-3 cells or with 
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the scrambled constructs. Figure 4 shows a representation of this for fluorescently-labelled 
GnRH-1 analogue 4 (has the highest cellular uptake in flow studies, Figures 2 and 3) where 
granules were present inside the PC-3 cells (Figure 4B) but were absent from the SKOV-3 
cells (Figure 4D). Analogue 6 also showed significant uptake (Figure 2 and 3), but as the 
uptake was lower than 4, it was not investigated further.  
 
Cellular uptake of analogue 4 using confocal microscopy (Figure 5) in the absence 
and presence of competitor triptorelin was performed. Here, the nucleus is stained with 
DAPI, the GnRH-1 analogue is labelled with a fluorescent tag (5-FAM), and the cell 
membrane stained with Alexa Fluor 647. In the absence of triptorelin, granule formation is 
observed in the cytosol of PC-3 cells but negligible uptake is observed when triptorelin is 
present. In receptor negative SKOS-3 cells, no internalisation is observed in the absence or 
presence of triptorelin; however, non-specific binding localised to the outer cell membrane is 
observed in both cell lines and is not inhibited by triptorelin treatment. Localisation of the 
GnRH-1 analogue appears to be isolated to the cytosol with negligible present in the nucleus. 
 
Tumour cell growth study 
GnRH-1 dendrimers and triptorelin were studied for their direct antiproliferative 
properties on three prostate cancer cell lines, PC-3, LNCaP and DU145. None of the GnRH-1 
analogues, including the control peptide triptorelin, produced significant growth alteration in 
PC-3 and LNCaP cells at 25 and 50 µM concentrations (Figure 6a and b). However, with the 
exception of 5, all compounds produced significant cell growth inhibitory effects on DU145 
cells in a preliminary study at 25 and 50 µM. Further experiments were performed on DU145 
cells using a broader range of GnRH-1 analogue concentrations (10, 50, 100 and 200 µM) to 
obtain the maximum possible effect (Figure 6c), and 1, 10, 25, 50, 100 and 200 µM to 
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calculate the IC50. From dose-response curves obtained for GnRH-1 analogues including 
triptorelin, it was shown that all compounds except 5 induced dose-dependent cell growth 
suppression with IC50 values between 22 µM for analogue 1 and 35 µM for analogue 4 (Table 
3). This effect of the compound was higher than that of triptorelin with an IC50 value of 78 
µM. Compound 5 produced significant reduction in the viability of DU145 cells (35%) only 
at 50 µM (p<0.05).  
 
Evaluation of GnRH-1 analogues toxicity on PBMCs 
Cell toxicity of dendrimers 1-6 was evaluated in normal PBMCs isolated from whole 
blood. All compounds were found to be non-toxic to PBMCs at the two concentrations used 
for cancer cell proliferation studies (Figure 6d). A slight increase in the proliferation (20-
30%) was observed in the cells treated with compounds 2, 5 and 6 at the lower concentration, 
25 µM. 
 
Discussion 
GnRH-1 analogues used in this study contained either two GnRH-1 epitopes 
organised in a dendritic manner (Figure 1; 1, 3, and 5) or two GnRH-1 epitopes presented in a 
linear fashion (Figure 1; 2, 4, and 6). The N-termini of analogues 3 and 4 contain C12-LAA 
groups compared to an internal [26] placement in analogues 1 and 2. Peptides containing no 
lipids (5 and 6), or a scrambled GnRH-1 analogue (s1-s4) were used as controls.  
 
C12-LAA [14] combines essential features of amino acids and lipids and was added at 
different positions to investigate the potential of GnRH-1 dendrimers to target prostate cancer 
cells. The polar head group of C12-LAA allows for the facile inclusion into any peptide 
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sequence, and the solubility and hydrophobicity can be balanced by choosing an appropriate 
alkyl chain length.[21] 
 
Replacement of pyroglutamic acid with glutamine was essential to enable N-terminal 
extension of the GnRH peptide. Glutamine is present in the endogenously synthesised peptide 
and under-goes spontaneous cyclisation to pyroglutamic acid, although the reaction rate of 
the latter is considerably higher.[14] All peptides were labelled with a fluorescent tag at their 
N-terminus to enable in vitro visualisation.[27] 
 
Fusion peptides (with a visual tag) are an important tool for evaluating receptor 
synthesis, transport to the plasma membrane and internalisation kinetics.[28] It is unknown 
whether the attachment of a fluorescent tag to these constructs will alter their rate or 
mechanism of internalisation.[28, 29] A study which attached GFP to the C-terminus of the 
GnRH peptide was shown to have no significant effect on receptor-mediated internalisation 
kinetics compared to its radiolabelled counterpart.[28, 29] N-terminal extension by 
Blanchfield et al by addition of lipids to glutamic acid indicated that the GnRH-derivative 
was still active in oral delivery studies.[30] However, it is not known what effect addition of 
lipids and a fluorescent tag will have on GnRH binding and uptake of these dendritic 
compounds. To date, none of the amino acids in the GnRH sequence appear to be essential 
for receptor activation.[31]  
 
Recently there has been an increased interest in identifying nanoparticle 
characteristics that are best suited to drug delivery applications. Many studies have 
demonstrated that nanoparticle size is a major factor affecting particle distribution into 
tumours. In general, nanoparticles smaller than 100 nm are considered best for tumour 
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targeting. However, particles sub-20 nm had rapid accumulation in tumour cells but poor 
retention, and particles greater than 100 nm have low tumour permeability. It has been shown 
that the cell surface charge of nanoparticles is also an important factor in cellular uptake.[32-
34] Positively charged nanoparticles are rapidly taken up by tumour cells but can lead to 
significant immune reactions, hence neutral and negatively charged nanoparticles are 
preferable for clinical applications.[32-34] Taking into account this information and the size 
of the particles formed in this study (greater than 100 nm), these particles were expected to 
have low permeability into tumour cells, highlighting the requirement for receptor-mediated 
endocytosis for cellular internalisation. Additionally, N-terminally bound analogues 1 and 3 
are smaller in size compared to their C-terminally bound counterparts and, as expected, the 
analogues with two linear epitopes (1 and 2) were larger than the analogues with single linear 
epitopes (3 and 4) indicating different rearrangement properties.  
 
Cellular internalisation of GnRH-1 analogues to PC-3 cells relative to SKOV-3 cells 
(Figure 2) indicated the importance of the bi-GnRH-1 sequence for internalisation. Here, a 
negligible difference in internalisation of lipidated analogues 2, s2, 4, and s4 were observed 
between both cell lines (Figure 2). However, a significant difference in internalisation was 
observed for the non-lipidated analogue 6 when compared to PC-3 cells and the lipidated 
analogues (2, s2, 4, and s4). No significant difference was observed in fluorescence between 
mono-GnRH-1 analogues that contained lipids in either C- or N-terminal orientations when 
compared to the non-lipidated analogue 5 (Figure 2).  
Flow cytometry (Figure 3) showed that PC-3 cells incubated with GnRH-1 analogues 
had higher cellular association and internalisation than SKOV-3 cells. However, significant 
quenching of surface-bound fluorescence by TB was observed for all analogues in both cell 
lines (Figure 3). Quenching studies using TB eliminated the presence of externally bound 
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constructs although analogues s1-s4 still exhibited a moderate to strong fluorescent signal, 
implying non-GnRH receptor mediated cellular association. This was supported by previous 
knowledge that inclusion of lipids into peptides was responsible for irreversible cell binding 
which would not be dissociated with extensive washing or trypsin treatment. A study 
investigating the extent of cellular penetration was influenced by the lipid moieties attached 
to the GnRH-derivative. They also found that the lipopeptides crossed the cellular cytoplasm 
and endoplasmic reticulum.[35, 36] The extent of binding was contributed to the increased 
toxicity of some compounds.[35, 36] Additionally, non-invasive cellular import of the 
synthetic peptide was achieved by covalent modification of a peptide chain by adding 
lipids.[36] 
Previous studies showed that receptor-mediated internalisation of GnRH analogues, 
such as AN-152, could be inhibited by preincubation of the cells with triptorelin.[6, 7, 37-40] 
The cellular uptake of analogue 4 was examined in the presence and absence of competitor 
triptorelin (100x excess) in separate experiments by confocal microscopy. Non-specific 
binding of the GnRH-derivative, as observed in Figure 4 where fluorescently-labelled 
analogue 4 bound to the membrane of both SKOV-3 and PC-3 cells, precluded flow 
cytometry as a suitable measure of cellular uptake and inhibition. In the absence of 
triptorelin, uptake was seen in the form of highly fluorescent punctuate bodies in the 
cytoplasm of receptor positive PC-3 cells but absent in SKOV-3 cells which express low 
levels of GnRH receptors (Figure 5). In the presence of triptorelin minimal uptake was 
observed in PC-3 cells and no internalisation was seen in SKOV-3 cells (Figure 5). Non-
specific binding in the periphery of the cells from both cell lines is also apparent in these 
images. This competition study found that uptake mediated by the GnRH-receptor was 
competitively inhibited by simultaneous treatment with an excess of the GnRH agonist 
triptorelin.[37-40]  
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The three classic prostate cancer cell lines, PC-3, LNCaP and DU145, which are the 
most widely used prostate cancer cells, were used to examine the effect of our GnRH-1 
analogues on the proliferation of cells. PC-3, LNCaP, and DU145 over express GnRH 
receptors; however their androgen receptor status and some characteristics such as the 
presence and type of prostate specific antigen (PSA), p53, prostatic acid phosphatase (PAP), 
are different in each cell line.[41] Activation of GnRH receptors in different cell lines derived 
from human reproductive tissues has been shown to directly inhibit cell growth. However, 
contradictory data exist showing the absence of sensitivity of some cell lines to the growth 
inhibitory effect of GnRH analogues, which bind to the GnRH receptor.[42] This was 
consistent with our findings where GnRH derivatives did not affect the viability of the 
GnRH-receptor positive cells, PC-3 and LNCaP. LNCaP has previously been showed to elicit 
proliferative response to GnRH analogues.[42] Factors such as estrogen, insulin-like growth 
factors, or members of the epidermal growth factor family may counteract the growth 
inhibitory effects of GnRH analogues.[43] In contrast to the poor effect of the analogues on 
LNCaP and PC-3 cells, all lipid-modified compounds, as well as compound 6, produced 
significant dose-dependent growth suppression in DU145 cells. Analogue 5, which did not 
produce a dose-dependent growth inhibition, was the only compound not bearing any lipid 
and having only one copy of GnRH-1 in each branch. It was shown previously that 
combinatorial action with growth factor inhibitors is required in some cells to enhance the 
anti-proliferative effects of GnRH analogues. In a prior study GnRH agonist-mediated 
inhibition of DU145 cells was shown to be due to a decreased epidermal growth factor 
receptor (EGFR) level.[44] A direct antiproliferative characteristic for a GnRH receptor-
mediated carrier is an added benefit to the targeted delivery of cytotoxic compounds. 
Conjugation of a carrier with growth inhibitory activity to an anticancer compound may 
reinforce the cytotoxic activity against GnRH receptor expressing tumor cells. 
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These studies show promising results for the use of lipidated dendritic GnRH-1 
peptides as scaffolds for cytotoxic drug delivery to tumour cells by binding and 
internalisation via GnRH receptors. Further investigation into the mechanism of uptake in the 
presence of a cytotoxic drug in vitro will be useful to establish the efficacy of this system in 
therapeutic applications.  
 
In summary, we showed the facile synthesis of several fluorescent GnRH-1 analogues 
including lipoamino acids in different positions of the peptide sequence. Derivative 4 showed 
uptake in receptor positive PC-3 cells as confirmed by confocal microscopy. Absence of 
uptake was observed in SKOV-3 cells which express low level GnRH receptors. Non-specific 
binding to the cell membranes for both cell lines was confirmed using TB quenching studies 
with analysis by flow cytometry and microscopy. Future assays aim to investigate analogue 6 
for uptake and internalisation. This investigation showed it was possible to develop 
fluorescently-labelled lipidated dendritic GnRH analogues, which can be selectively 
internalised for potential use in cell targeting applications.  
 
Conclusion 
The present study provides evidence that dendritic GnRH-1 analogues facilitated 
specific uptake by prostate cancer cells that overexpress the GnRH receptor. Additionally, 
our results showed that non-specific binding was increased when a lipid was present in the 
compound but did not lead to cellular internalisation. A direct growth inhibitory action of the 
lipidic GnRH-1 dendrimers was observed in androgen-receptor negative prostate cancer cells, 
DU145. These results support the premise that GnRH-1 analogues have potential value in 
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future drug targeting applications to treat human cancers in addition to applications in the 
field of vaccine development.  
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Figures  
 
Figure 1. Library of GnRH-1 analogues. GnRH-1 sequence Gln-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly for peptides 1-6 or a scrambled (s) entity, Ser-Trp-Gly-Leu-His-Pro-Gln-Gly-
Try-Arg for peptides s1-s4. *5(6)-carboxyfluorescein (5-FAM).  
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Figure 2. Internalisation data of GnRH-1 analogues after 4 hours incubation with PC-3 and 
SKOV-3 cells. The intracellular fluorescence was measured after the cell surface-bound 
fluorescence was quenched by 0.4% trypan blue. The binding index was normalised against 
the negative control (Neg. Ctl., cells only) in order to normalise binding of each cell type. 
Negative control (Neg. Ctl.) is cells only. Each value represents mean ±SD for triplicate 
samples. (ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001) 
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Figure 3. Quantitative data from flow cytometry showing the average intracellular and cell 
surface-bound fluorescence of FAM labelled GnRH-1 analogues after 4 h incubation with 
PC-3 cells (A) and SKOV-3 cells (B). Average cell-associated fluorescence was quantified 
by flow cytometry. Intracellular fluorescence was measured after the cell surface-bound 
fluorescence was quenched by 0.4% trypan blue. Cell surface-bound fluorescence is the 
difference between the total cell associated fluorescence and the intracellular fluorescence. 
Each value represents mean ±SD for triplicate samples. 
 
 
A 
 
 
 
 
B 
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Figure 4. In vitro cellular uptake of fluorescently-labelled analogue 4 in PC-3 (A-B) and 
SKOV-3 (C-D) cells. Cells were plated in 24-well plates. 5-FAM labelled peptide analogue 
(green) were added to the cells and incubated for 4 h at 37 °C and imaged under bright field 
(A, C) or fluorescence (B, D) microscopy. A-B 20x, C-D 10x.  
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Figure 5. In vitro cellular uptake of analogue 4 in SKOV-3 and PC-3 cells in the presence and 
absence of competitor triptorelin (100× excess). Cells were plated on culture slides. 5-FAM-
labelled GnRH-1 analogues (green) were added to the cells and incubated in the presence and 
absence of triptorelin for 4 h at 37 °C. Membranes were stained with Alexa Fluor 647 (red). 
Nuclei were stained with DAPI (blue). Analysis was performed on an Olympus BX61 upright 
confocal microscope at 60x using oil immersion. 
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Figure 6. Viability of (a) PC-3, (b) LNCaP, (c) DU-145 cells and (d) PBMCs as a percentage 
of cells treated with PBS (mean ±SEM) after 48 hours incubation with compounds 1-6, 
GnRH and triptorelin ([w
6
]-GnRH) in 10% DMSO. Statistical analysis was performed using 
a one-way ANOVA followed by the Dunnett’s post hoc test and compared to DMSO group 
(*, p > 0.05; ***, p < 0.001). 
 
Tables 
Table 1. Purification yields and characterisation of GnRH-1 analogues by RP-HPLC and MS 
* 
MeOH gradient, 
ʈ
 MeCN gradient, ‡ C8 Vydac column,
 §
C18 Vydac column  
Table 2. Particle size and polydispersity index (PDI) of GnRH-1 analogues measured in 
triplicate. Dynamic light scattering analysis was performed at 25 °C and a scattering angle of 
Analogue 
Yield 
mg (%) 
RP-HPLC retention time (min) MS 
C4 Vydac 
Column
*
 
C4 Vydac 
Column
 ʈ
 
Ionisation
 
Calculated Found 
1 7.5 mg (35%) 18.18 24.7 [M+2H]
+2
 1840.06 1840.7 
s1 8.0 mg (40%) 15.2 15.0 [M+2H]
+2
 1840.06 1839.8 
2 8.4 mg (42%) 23.06 16.9 [M+3H]
+3
 2013.96 2015.4 
s2 5.2 mg (25%) 17.5 17.8 [M+3H]
+3
 2013.96 2015.4 
3 12.6 mg (63%) 23.03 18.0 [M+2H]
+2
 1838.87 1841.1 
s3 5.6 mg (28%) 19.9, 20.2 19.0, 20.1 [M+2H]
+2
 1838.87 1840.4 
4 5.0 mg (25%) 23.00 16.9 [M+3H]
+3
 2013.96 2015.1 
s4 20.5 mg (63%) 18.5 20.1 [M+4H]
+4
 1510.72 1511.9 
5 12.2 mg (61%) 15.38
 ʈ  ,‡ 15.3
§
 [M+2H]
+2
 1641.69 1643.3 
6 4.4 mg (22%) 15.30
 ʈ  ,‡ 13.0
§
 [M+2H]
+2
 2823.26 2822.8 
Triptorelin 9.5 mg (27%) 18.0
 ʈ  ,‡ 18.0
§
 [M+1H]
+1
 1311.64 1312.3 
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173°. The particle suspension was diluted appropriately in distilled water before 
measurement.  
 
Compound Particle Size (nm) PDI 
1  675.2 ± 34.5 0.21 ± 0.01 
2  603.6 ± 8.3 0.13 ± 0.07 
3  246.3 ± 0.6 0.29 ± 0.01 
4  203.2 ± 3.8 0.32 ± 0.02 
 
 
 
 
Table 3. IC50 values obtained after treatment of DU145 cells with the test compounds. 
 1 2 3 4 5 6 Triptorelin 
IC50 in  
DU145 cells 
(µM) 
22 ± 1.02 26 ± 1.58 25 ± 1.08 35 ± 2.03 >200 32 ± 1.75 78 ± 5.54 
 
 
 
